Tivozanib for hepatocellular carcinoma: not likely a new option

Detalles Bibliográficos
Autores principales: Estrade, Florian, Le Du, Fanny, Crouzet, Laurence, Bourien, Héloïse, Muzellec, Léa, Edeline, Julien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Editorial Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7723626/
https://www.ncbi.nlm.nih.gov/pubmed/33313082
http://dx.doi.org/10.21037/atm-20-3389
_version_ 1783620380792979456
author Estrade, Florian
Le Du, Fanny
Crouzet, Laurence
Bourien, Héloïse
Muzellec, Léa
Edeline, Julien
author_facet Estrade, Florian
Le Du, Fanny
Crouzet, Laurence
Bourien, Héloïse
Muzellec, Léa
Edeline, Julien
author_sort Estrade, Florian
collection PubMed
description
format Online
Article
Text
id pubmed-7723626
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-77236262020-12-10 Tivozanib for hepatocellular carcinoma: not likely a new option Estrade, Florian Le Du, Fanny Crouzet, Laurence Bourien, Héloïse Muzellec, Léa Edeline, Julien Ann Transl Med Editorial Commentary AME Publishing Company 2020-11 /pmc/articles/PMC7723626/ /pubmed/33313082 http://dx.doi.org/10.21037/atm-20-3389 Text en 2020 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Editorial Commentary
Estrade, Florian
Le Du, Fanny
Crouzet, Laurence
Bourien, Héloïse
Muzellec, Léa
Edeline, Julien
Tivozanib for hepatocellular carcinoma: not likely a new option
title Tivozanib for hepatocellular carcinoma: not likely a new option
title_full Tivozanib for hepatocellular carcinoma: not likely a new option
title_fullStr Tivozanib for hepatocellular carcinoma: not likely a new option
title_full_unstemmed Tivozanib for hepatocellular carcinoma: not likely a new option
title_short Tivozanib for hepatocellular carcinoma: not likely a new option
title_sort tivozanib for hepatocellular carcinoma: not likely a new option
topic Editorial Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7723626/
https://www.ncbi.nlm.nih.gov/pubmed/33313082
http://dx.doi.org/10.21037/atm-20-3389
work_keys_str_mv AT estradeflorian tivozanibforhepatocellularcarcinomanotlikelyanewoption
AT ledufanny tivozanibforhepatocellularcarcinomanotlikelyanewoption
AT crouzetlaurence tivozanibforhepatocellularcarcinomanotlikelyanewoption
AT bourienheloise tivozanibforhepatocellularcarcinomanotlikelyanewoption
AT muzelleclea tivozanibforhepatocellularcarcinomanotlikelyanewoption
AT edelinejulien tivozanibforhepatocellularcarcinomanotlikelyanewoption

Ejemplares similares